GSK’s pay-for-delay judgment — handed down by judges at the EU’s top court earlier this year — may be the “end of an era” for the EU’s antitrust regulator, allowing it to refocus enforcement efforts elsewhere in the pharmaceutical sector, an EU competition official has said."For the past decade we have been essentially investigating